{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:55:22Z","timestamp":1794282922684,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vascn.2021.107067","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T22:14:33Z","timestamp":1618956873000},"page":"107067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies"],"prefix":"10.1016","volume":"109","author":[{"given":"Joel","family":"Baublits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Engwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2021.107067_bb0005","series-title":"ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals","author":"Anonymous","year":"2000"},{"key":"10.1016\/j.vascn.2021.107067_bb0010","series-title":"ICH E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non- antiarrhythmic drugs","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.vascn.2021.107067_bb0015","series-title":"ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","author":"Anonymous","year":"2005"},{"issue":"3","key":"10.1016\/j.vascn.2021.107067_bb0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pst.454","article-title":"Review of the statistical analysis of the dog telemetry study","volume":"10","author":"Aylott","year":"2011","journal-title":"Pharmaceutical Statistics"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vascn.2014.05.004","article-title":"Translational PK\/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development","volume":"70","author":"Caruso","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vascn.2007.04.002","article-title":"ILSI-HESI cardiovascular safety subcommittee dataset: An analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc)","volume":"56","author":"Chiang","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2021.107067_bb1010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vascn.2018.02.009","article-title":"The evaluation of endpoint variability and implications for study statistical power and sample size in conscious instrumented dogs","volume":"92","author":"Chiang","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.vascn.2010.05.013","article-title":"Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT\/QTc interval prolongation","volume":"62","author":"Chiang","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vascn.2012.05.002","article-title":"Comprehensive analysis of cardiac arrhythmias in telemetered cynomolgus monkeys over a 6 month period","volume":"66","author":"Chui","year":"2012","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vascn.2009.04.196","article-title":"Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants","volume":"60","author":"Chui","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.vascn.2009.05.004","article-title":"A comparison of three software platforms for automated ECG analysis","volume":"60","author":"Chui","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bph.12484","article-title":"Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: Comparison with implanted telemetry","volume":"171","author":"Derakhchan","year":"2014","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicological Sciences"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.vascn.2013.04.008","article-title":"A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions","volume":"68","author":"Ewart","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"issue":"17","key":"10.1016\/j.vascn.2021.107067_bb0075","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1111\/bph.13218","article-title":"Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis","volume":"172","author":"Gotta","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2021.107067_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2014.12.008","article-title":"Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing","volume":"72","author":"Gotta","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2021.107067_bb0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vascn.2009.05.006","article-title":"Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies","volume":"60","author":"Guth","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2021.107067_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.vascn.2004.02.006","article-title":"Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization","volume":"49","author":"Guth","year":"2004","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2021.107067_bb0095","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0008-6363(00)00310-2","article-title":"Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey","volume":"49","author":"Hammond","year":"2001","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vascn.2013.05.004","article-title":"Preclinical QT safety assessment: Cross-species comparisons and human translation from an industry consortium","volume":"69","author":"Holzgrefe","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2021.107067_bb0105","doi-asserted-by":"crossref","first-page":"106606","DOI":"10.1016\/j.vascn.2019.106606","article-title":"Exposure-response analysis of drug-induced QT interval prolongation in telemetered monkeys for translational prediction to human","volume":"99","author":"Komatsu","year":"2018","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2021.107067_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vascn.2015.05.008","article-title":"Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed telemetry-blood pressure (JET-BP)","volume":"75","author":"Kremer","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2021.107067_bb0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2011.08.006","article-title":"Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society","volume":"65","author":"Leishman","year":"2012","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vascn.2013.04.006","article-title":"Intravenous solid tip ECG lead placement in telemetry implanted dogs: Part 2: High quality telemetry signals yield high sensitivity to drug-induced changes","volume":"68","author":"Mitchell","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"5","key":"10.1016\/j.vascn.2021.107067_bb0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1538\/expanim.51.465","article-title":"Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs","volume":"51","author":"Miyazaki","year":"2002","journal-title":"Experimental Animals"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicological Sciences"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2010.05.011","article-title":"Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power","volume":"62","author":"Sivarajah","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2021.107067_bb0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14740338.2013.745851","article-title":"Nonclinical strategy considerations for safety pharmacology: Evaluation of biopharmaceuticals","volume":"12","author":"Vargas","year":"2013","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.vascn.2021.107067_bb0150","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","author":"Vargas","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"}],"updated-by":[{"DOI":"10.1016\/j.vascn.2021.107104","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871921001192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871921001192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:04:14Z","timestamp":1761005054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871921001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"alternative-id":["S1056871921001192"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2021.107067","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2021.107067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107067"}}